This paper is in the following e-collection/theme issue:

Pharmacovigilance (133) Adverse Drug Events Detection, Pharmacovigilance and Surveillance (155) Natural Language Processing (690) Prevention and Health Promotion (986) Artificial Intelligence (1369)

Published on in Vol 9 (2023)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/40080, first published .
Reporting, Monitoring, and Handling of Adverse Drug Reactions in Australia: Scoping Review

Reporting, Monitoring, and Handling of Adverse Drug Reactions in Australia: Scoping Review

Reporting, Monitoring, and Handling of Adverse Drug Reactions in Australia: Scoping Review

Authors of this article:

Joel Fossouo Tagne1, 2, 3 Author Orcid Image ;   Reginald Amin Yakob4 Author Orcid Image ;   Thu Ha Dang5, 6 Author Orcid Image ;   Rachael Mcdonald3, 7, 8 Author Orcid Image ;   Nilmini Wickramasinghe1, 8, 9 Author Orcid Image
Article Authors Cited by (12) Tweetations (4) Metrics

Journals

  1. Fossouo Tagne J, Yakob R, Mcdonald R, Wickramasinghe N. Linking Activity Theory Within User-Centered Design: Novel Framework to Inform Design and Evaluation of Adverse Drug Reaction Reporting Systems in Pharmacy. JMIR Human Factors 2023;10:e43529 View
  2. Valinciute A, Gerbutaviciene R, Paukstaitiene R, Kubiliene L. Pharmacovigilance and Adverse Drug Reaction Reporting among the General Public in Lithuania: A Cross-Sectional Study. Healthcare 2023;11(8):1133 View
  3. Mhaidat N, Alshogran O, Altawalbeh S, Jaber J, Banat H, Ahmad D, Alabsi W. Patterns of adverse drug reactions in Jordan: a retrospective analysis of the National Pharmacovigilance Data Registry (2015–2021). Expert Opinion on Drug Safety 2023;22(10):957 View
  4. Fossouo Tagne J, Yakob R, Mcdonald R, Wickramasinghe N. A Web-Based Tool to Report Adverse Drug Reactions by Community Pharmacists in Australia: Usability Testing Study. JMIR Formative Research 2023;7:e48976 View
  5. Liao J, Zhan Y, Zhang Z, Cui J, Yin J. HLA-targeted sequencing reveals the pathogenic role of HLA-B*15:02/HLA-B*13:01 in albendazole-induced liver failure: a case report and a review of the literature. Frontiers in Pharmacology 2023;14 View
  6. Chen W, Li S, Huang D, Su Y. Drugs associated with a risk of supraventricular tachycardia: analysis using the OpenVigil database. Journal of International Medical Research 2024;52(3) View
  7. Lin S, Lei S, Liu W, Zhu X, Yin L, Liu Q, Feng B. Global trends in pharmacovigilance-related events: a 30-year analysis from the 2019 global burden of disease study. International Journal of Clinical Pharmacy 2024;46(5):1076 View
  8. Selva P, Durairajan S. Exploration and Evaluation of Adverse Drug Reactions Documented in a Tertiary-Care Hospital in Chennai: An In-Depth Retrospective Observational Study. Cureus 2024 View
  9. Mulkalwar S, Chitale S, Dandage P, Bapat S, Tilak A, Patil S. Evaluation of the Effectiveness of the Adverse Drug Reaction Alert Card System in Preventing the Recurrence of Adverse Drug Reactions. Cureus 2024 View
  10. Cheng W, Du J, Chen C, Cao J, Xia X, Yang X, Zhang W, Jia X, Qi Y. Exploring the influencing factors of adverse drug reaction reporting among medical personnel: a COM-B model-based study. Journal of Pharmaceutical Policy and Practice 2024;17(1) View
  11. Deutscher B, Falconer N, De Guzman K, La Caze A. A scoping review of the clinical utility of adverse drug reaction causality analysis tools for use in the hospital setting. Expert Review of Clinical Pharmacology 2024 View
  12. Gebreyohannes E, Thornton C, Thiessen M, de Vries S, Andrade A, Kalisch Ellett L, Frank O, Cheah P, Choo K, Laba T, Roughead E, Hwang I, Moses G, Lim R. Co-designing a consumer-focused digital reporting health platform to improve adverse medicine event reporting: Protocol for a multi-method research project (the ReMedi project) (Preprint). JMIR Research Protocols 2024 View